PD-1 Inhibitor Drugs Market Surges with Expanding Immunotherapy Applications, Set to Cross $201.5 Billion by 2035 | Latest Report by TMR
04 mars 2025 07h09 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. – , March 04, 2025 (GLOBE NEWSWIRE) -- The Global PD-1 Inhibitor Drugs Market, valued at US$ 41.4 billion in 2024, is set for...
PD-1 x VEGF and PD-L1 x VEGF Bispecific Antibodies Business, Pipeline and Competitor Analysis Report 2025: Comprehensive Overview of R&D and Partnering Activities of Pharma and Technology Companies
03 mars 2025 07h44 HE
|
Research and Markets
Dublin, March 03, 2025 (GLOBE NEWSWIRE) -- The "PD-1 x VEGF and PD-L1 x VEGF Bispecific Antibodies: A Business, Pipeline And Competitor Analysis From An Industry Perspective" report has been added...
Gastric Cancer Market Research by Diagnosis, Treatment, Route of Administration, End-users, and Region - Global Market to Grow by Over $15 Billion During 2023-2034
23 janv. 2025 04h48 HE
|
Research and Markets
Dublin, Jan. 23, 2025 (GLOBE NEWSWIRE) -- The "Gastric Cancer Market by Type, by Diagnosis, by Treatment, by Route of Administration, by End-users, and by Region" report has been added to ...
Gastric Cancer Industry Analysis and Forecast to 2034 - Insights on the Global Market's Rapid Growth to $18.43 Billion, Emerging Therapies, and Regional Trends
20 nov. 2024 07h55 HE
|
Research and Markets
Dublin, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The "Gastric Cancer Market by Type, by Diagnosis, by Treatment, by Route of Administration, by End-users, and by Region" report has been added to ...
Global Immune Checkpoint Inhibitors Market Analysis Report 2024-2030: Growing FDA Approvals of Immune Checkpoint Inhibitors and Increasing Funding for Advancing Cancer Immunotherapy
24 juin 2024 10h26 HE
|
Research and Markets
Dublin, June 24, 2024 (GLOBE NEWSWIRE) -- The "Global Immune Checkpoint Inhibitors Market Size, Share & Trends Analysis Report by Type (PD-1, PD-L1, CTLA-4), Application (Lung Cancer, Breast...
Immune Checkpoint Drugs in Oncology: Analytical Tool – A Must-Have Handbook for Business Developers, BI/CI Operatives, and Clinical Developers
25 avr. 2024 10h26 HE
|
Research and Markets
Dublin, April 25, 2024 (GLOBE NEWSWIRE) -- The "Immune-checkpoint Drugs in Oncology: Analytical Tool" report has been added to ResearchAndMarkets.com's offering.Cancer cells sometimes find ways to...
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
16 janv. 2024 17h01 HE
|
Adagene Inc.
- Data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks (Q3W) in dose expansion showed clinical benefit including confirmed responses at higher, more frequent and...
Lerapolturev (Formerly Known as PVSRIPO) + Pembrolizumab for Glioblastoma Multiforme (GBM): Emerging Drug Insights and Market Forecast Report, 2019-2023 & 2023-2032
22 nov. 2023 08h58 HE
|
Research and Markets
Dublin, Nov. 22, 2023 (GLOBE NEWSWIRE) -- The "Lerapolturev + Pembrolizumab Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This report...
Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Advanced Cutaneous Melanoma
15 nov. 2023 09h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided updated data from an ongoing Phase 1b/2 clinical trial of investigational cancer immunotherapy PV-10 (rose...
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
22 oct. 2023 06h01 HE
|
HOOKIPA Pharma Inc.
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line setting—doubling historical ORR reported with...